ARTICLE | Product Development
Dec. 9 Quick Takes: Trio of biotechs parlays data into follow-ons
Plus: Erasca adds pan-RAF inhibitor from Novartis, and updates from UCB, Ambrx, Pharvaris and more
December 10, 2022 12:01 AM UTC
Prometheus Biosciences Inc. (NASDAQ:RXDX), Replimune Group Inc. (NASDAQ:REPL) and Autolus Therapeutics plc (NASDAQ:AUTL) all raised follow-ons on the back of clinical data released this week. San Diego biotech Prometheus raised $500 million in its financing, double its proposed amount, after reporting strong Phase II efficacy and clean safety data for anti-TL1A mAb PRA023 in ulcerative colitis and Crohn’s disease.
Replimune priced an upsized $225 million deal on the back of Phase I melanoma data for vusolimogene oderparepvec, while Autolus raised $150 million after anti-CD19 CAR therapy obecabtagene autoleucel met the pivotal Phase II endpoint in an acute lymphoblastic leukemia study. ...